Best Peptides for Inflammation Research

Quick research summary. The published inflammation research literature spans cell-culture, isolated-tissue and small-animal model studies of NF-kB signalling, inflammasome activation, cytokine networks, resolution biology, and chronic-inflammation pathways. Several peptide families appear in this research record. None is a licensed UK anti-inflammatory medicine in the research-use-only category.

Inflammation biology context

Inflammation literature spans the innate and adaptive immune systems, cytokine networks (TNF-alpha, IL-1, IL-6, IFN-gamma and many others), the NF-kB and MAPK signalling pathways, the inflammasome family (NLRP3 and others), and resolution biology including specialised pro-resolving mediators. Each axis has its own substantial peer-reviewed literature and many MHRA-licensed prescription anti-inflammatory medicines exist outside the research-peptide category.

Compound families that appear in the published inflammation research record

Cell-culture and animal-model studies have discussed several peptide families in inflammation contexts, including thymosin-alpha 1 in immune-modulation research, copper peptides such as GHK-Cu in oxidative and inflammatory biology, and several gut-derived peptides (including BPC-157) in intestinal inflammation models. None is a licensed UK anti-inflammatory treatment.

UK regulatory position

No research-use-only peptide on this site is a licensed anti-inflammatory medicine in the UK. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. Marketing peptides as anti-inflammatory interventions falls inside the medicines framework.

For laboratory researchers

Inflammation researchers may use peptide reference compounds for in-vitro cytokine and signalling studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling.